

WHO Expert Committee on Drug Dependence

Thirty-seventh report



World Health
Organization

The World Health Organization was established in 1948 as a specialized agency of the United Nations serving as the directing and coordinating authority for international health matters and public health. One of WHO's constitutional functions is to provide objective and reliable information and advice in the field of human health, a responsibility that it fulfils in part through its extensive programme of publications.

The Organization seeks through its publications to support national health strategies and address the most pressing public health concerns of populations around the world. To respond to the needs of Member States at all levels of development, WHO publishes practical manuals, handbooks and training material for specific categories of health workers; internationally applicable guidelines and standards; reviews and analyses of health policies, programmes and research; and state-of-the-art consensus reports that offer technical advice and recommendations for decision-makers. These books are closely tied to the Organization's priority activities, encompassing disease prevention and control, the development of equitable health systems based on primary health care, and health promotion for individuals and communities. Progress towards better health for all also demands the global dissemination and exchange of information that draws on the knowledge and experience of all WHO's Member countries and the collaboration of world leaders in public health and the biomedical sciences. To ensure the widest possible availability of authoritative information and guidance on health matters, WHO secures the broad international distribution of its publications and encourages their translation and adaptation. By helping to promote and protect health and prevent and control disease throughout the world, WHO's books contribute to achieving the Organization's principal objective – the attainment by all people of the highest possible level of health.

The WHO Technical Report Series makes available the findings of various international groups of experts that provide WHO with the latest scientific and technical advice on a broad range of medical and public health subjects. Members of such expert groups serve without remuneration in their personal capacities rather than as representatives of governments or other bodies; their views do not necessarily reflect the decisions or the stated policy of WHO. An annual subscription to this series, comprising about four to six such reports, costs CHF 150.00/US\$ 80.00 (CHF 105.00/US\$ 126.00 in developing countries). For further information, please contact: WHO Press, World Health Organization, 20 avenue Appia, 1211 Geneva 27, Switzerland (tel. +41 22 791 3264; fax: +41 22 791 4857; email: bookorders@who.int; order online: <http://www.who.int/bookorders>).

W H O T e c h n i c a l R e p o r t S e r i e s
9 9 8

WHO Expert Committee on Drug Dependence

Thirty-seventh report

This report contains the views of an international group of experts, and does not necessarily represent the decisions or the stated policy of the World Health Organization



**World Health
Organization**

WHO Expert Committee on Drug Dependence : thirty-seventh report.

(WHO technical report series ; no. 998)

1.Psychotropic Drugs - classification. 2.Drug Evaluation. 3.Drug and Narcotic Control.
4.Drugs, Essential – supply and distribution. 5.International Cooperation. I.World Health
Organization. II.WHO Expert Committee on Drug Dependence. Meeting (37th: 2015:
Geneva, Switzerland). III.Series.

ISBN 978 92 4 120998 4 (print)

(NLM classification: WM 270)

ISBN 978 92 4 069555 9 (PDF)

ISSN 0512-3054

©World Health Organization 2016

All rights reserved. Publications of the World Health Organization are available on the WHO website (<http://www.who.int>) or can be purchased from WHO Press, World Health Organization, 20 Avenue Appia, 1211 Geneva 27, Switzerland (tel.: +41 22 791 3264; fax: +41 22 791 4857; email: bookorders@who.int).

Requests for permission to reproduce or translate WHO publications – whether for sale or for non-commercial distribution – should be addressed to WHO Press through the WHO website (http://www.who.int/about/licensing/copyright_form/index.html).

The designations employed and the presentation of the material in this publication do not imply the expression of any opinion whatsoever on the part of the World Health Organization concerning the legal status of any country, territory, city or area or of its authorities, or concerning the delimitation of its frontiers or boundaries. Dotted and dashed lines on maps represent approximate border lines for which there may not yet be full agreement.

The mention of specific companies or of certain manufacturers' products does not imply that they are endorsed or recommended by the World Health Organization in preference to others of a similar nature that are not mentioned. Errors and omissions excepted, the names of proprietary products are distinguished by initial capital letters.

All reasonable precautions have been taken by the World Health Organization to verify the information contained in this publication. However, the published material is being distributed without warranty of any kind, either expressed or implied. The responsibility for the interpretation and use of the material lies with the reader. In no event shall the World Health Organization be liable for damages arising from its use.

This publication contains the collective views of an international group of experts and does not necessarily represent the decisions or the policies of the World Health Organization.

Layout L'IV Com Sàrl, Villars-sous-Yens, Switzerland.
Printed in Italy

Contents

WHO Expert Committee on Drug Dependence	v
Abbreviations	viii
Introduction	1
1. Work of international bodies concerned with controlled substances	4
1.1 Update from the International Narcotics Control Board	4
1.2 Update from the United Nations Office on Drugs and Crime	4
1.3 Update from Management of Substance Abuse Unit, WHO	5
1.4 Update from Essential Medicines and Health Products, WHO	6
2. Criteria for assessing new psychoactive substances	8
3. Terminology	9
4. Follow-up on recommendations made by the ECDD at its thirty-sixth meeting	10
4.1 Mephedrone	10
4.2 Ketamine (INN)	10
4.3 AH-7921	11
4.4 Gamma-butyrolactone (GBL)	11
4.5 1,4-Butanediol (1,4-BD)	12
4.6 25B-NBOMe	12
4.7 25C-NBOMe	12
4.8 25I-NBOMe	13
4.9 <i>N</i> -Benzylpiperazine (BZP)	13
4.10 JWH-018	13
4.11 AM-2201	14
4.12 3,4-Methylenedioxypyrovalerone (MDPV)	14
4.13 Methylone (BK-MDMA)	15
5. Critical review of psychoactive substances	16
5.1 MT-45	16
5.2 Acetylfentanyl	18
5.3 α -Pyrrolidinovalerophenone (α -PVP)	20
5.4 4-Fluoroamphetamine (4-FA)	21
5.5 <i>para</i> -Methyl-4-methylaminorex (4,4'-DMAR)	22
5.6 <i>para</i> -Methoxymethylamphetamine (PMMA)	24
5.7 Methoxetamine (MXE)	25
6. Pre-review of psychoactive substances	28
6.1 Etizolam (INN)	28
6.2 Phenazepam	30

7. Updates	32
7.1 Ketamine (INN)	32
7.2 Cannabis and cannabis resin	32
8. Future agenda items	33
Acknowledgements	34
References	34



WHO Expert Committee on Drug Dependence

Geneva, Switzerland, 16–20 November 2015

Members

Mrs Jehan Al-Fannah, Clinical Pharmacy Consultant in Paediatrics, Director of Pharmaceutical Care Department, Royal Hospital, Muscat, Sultanate of Oman

Professor Patrick M Beardsley, Professor of Pharmacology and Toxicology, Institute for Drug and Alcohol Studies & Center for Biomarker Research and Personalized Medicine, Virginia Commonwealth University, Richmond, VA, United States of America (*Rapporteur*)

Dr Bruna Brands, Senior Science Advisor, Office of Drug Science and Surveillance, Controlled Substances Directorate, Health Canada, Ottawa, Ontario, Canada (*Chair*)

Professor Rosa Buitrago, Clinical Pharmacist and Vice-Dean, Professor of Pharmacology and Cancer Pain Management and Palliative Care, School of Pharmacy, University of Panama, Panama

Dr Simon Elliott, Consultant Forensic Toxicologist and Managing Director of ROAR Forensics, Worcestershire, England

Dr Ifeoma Toyin Ekwere, Senior Consultant Anaesthesiologist, Department of Anaesthesiology, University of Benin Teaching Hospital, Benin City, Nigeria

Professor Raka Jain, Professor of Chemistry, Officer in Charge, Department of Psychiatry, National Drug Dependence Treatment Centre Laboratories, All India Institute of Medical Sciences, New Delhi, India

Dr Pamela Kaduri, Addiction Psychiatrist, Department of Psychiatry and Mental Health, Muhimbili National Hospital, Dar es Salaam, United Republic of Tanzania

Dr Parulian Sandy Noveria, Head of Medical, Directorate Medical and Nursing, Jakarta, Indonesia Drug Dependence Hospital, Jakarta, Indonesia

Dr Edmundus J.M. Pennings, Associate Professor of Forensic Toxicology, Maastricht University, The Netherlands, and Forensic Toxicologist, The Maastricht Forensic Institute, The Netherlands

Dr Emran Razaghi, Associate Professor of Psychiatry, Tehran University of Medical Sciences, Tehran, Islamic Republic of Iran

Professor Tsutomu Suzuki (Specially-Appointed and Emeritus), Drug Dependence Laboratory, School of Pharmacy and Pharmaceutical Sciences, Hoshi University, Tokyo, Japan

Professor Jason White, Professor of Pharmacology and Head, School of Pharmacy and Medical Sciences, Division of Health Sciences, University of South Australia, Adelaide, Australia (*Co-Chair*)

Representatives from other organizations

International Narcotics Control Board (INCB)

Ms Beate Hammond, Drug Control and Crime Prevention Officer, Secretariat of the INCB, United Nations Office on Drugs and Crime, Vienna, Austria

Dr Viroj Sumyai, Member of the INCB, Vienna, Austria

United Nations Office on Drugs and Crime (UNODC)

Dr Justice Tettey, Chief, Laboratory and Scientific Section, Research and Trend Analysis Branch, Division for Policy Analysis and Public Affairs, UNODC, Vienna, Austria

Secretariat

Dr Wim Best, Honorary Lecturer, Freudenthal Institut, Utrecht University, Utrecht, The Netherlands (*Temporary Adviser*)

Dr Simon D. Brandt, Reader in Bioactive Drug Chemistry, School of Pharmacy and Biomolecular Sciences, John Moores University, Liverpool, England (*Temporary Adviser*)

Dr Zurina Hassan, Senior Lecturer, Centre for Drug Research, Universiti Sains Malaysia, Penang, Malaysia (*Temporary Adviser*)

Dr Bertha K. Madras, Professor of Psychobiology, Department of Psychiatry, Harvard Medical School, McLean Hospital, Belmont, MA, United States of America (*Temporary Adviser*)

Dr Afarin Rahimi-Movaghar, Associate Professor of Psychiatry, Director of Iranian

预览已结束，完整报告链接和二维码如下：

https://www.yunbaogao.cn/report/index/report?reportId=5_27059

